7 Need-to-Know Things About Low-Grade Serous Ovarian Cancer

1. Low-Grade Serous Ovarian Cancer Is a Distinct and Rare Disease

Low-grade serous ovarian cancer is an epithelial ovarian cancer that may arise in the ovary, fallopian tube, or peritoneum. It accounts for only about 2% to 5% of ovarian cancers and approximately 5% to 10% of serous ovarian cancers. The average age at diagnosis is often estimated at 45 to 55, making patients younger, on average, than those diagnosed with high-grade serous ovarian cancer.

The term low-grade describes how the cells look under a microscope and how they tend to behave biologically. LGSOC cells usually appear less abnormal and divide more slowly than high-grade cancer cells. However, slower growth does not equal harmless growth. Many patients are diagnosed after the cancer has already reached the upper abdomen or lymph nodes.

LGSOC may occasionally develop alongside or after a serous borderline tumor. That connection is one reason a detailed review of previous pathology can be valuable, especially for someone who had a borderline ovarian tumor years earlier.

Low-grade and high-grade cancers are not interchangeable

Doctors now recognize low-grade and high-grade serous carcinomas as biologically different diseases rather than opposite ends of one spectrum. They frequently involve different molecular changes, affect different age groups, and respond differently to chemotherapy. A treatment plan should therefore be designed specifically for LGSOC, not copied and pasted from a high-grade ovarian cancer playbook.

2. The Symptoms Can Be Vague, Persistent, and Easy to Dismiss

Low-grade serous ovarian cancer generally produces the same types of symptoms seen with other epithelial ovarian cancers. Common warning signs include:

• Persistent abdominal bloating or swelling
• Pelvic or abdominal pain, pressure, or heaviness
• Feeling full after eating only a small amount
• Changes in bowel habits, including constipation
• Urinary urgency or increased frequency
• Nausea, indigestion, or reduced appetite
• Unexplained fatigue or back pain
• Irregular vaginal bleeding or menstrual changes

The frustrating part is that these symptoms can resemble ordinary digestive, urinary, or hormonal problems. Bloating after one ambitious pizza night is not automatically a cancer symptom. Bloating that is new, frequent, worsening, and present most days deserves more attention.

The American Cancer Society advises discussing symptoms that occur repeatedlyparticularly more than about 12 times per monthwith a healthcare professional. Patient organizations also encourage evaluation when symptoms remain for roughly two weeks despite ordinary measures such as dietary changes, rest, or constipation treatment.

There is no reliable routine screening test

Unlike cervical cancer, ovarian cancer cannot be screened for with a Pap test. There is currently no effective screening test for average-risk people that reliably detects LGSOC at an early stage. CA-125 blood testing and ultrasound may be useful during an evaluation, but neither is accurate enough to serve as a stand-alone screening tool.

CA-125 can rise because of cancer, but it can also increase because of noncancerous conditions. Some ovarian cancers produce little CA-125 at all. The test is often more useful for establishing a baseline and monitoring a known cancer than for answering the broad question, “Do I have ovarian cancer?”

3. Expert Pathology and Molecular Testing Matter More Than Ever

A definitive diagnosis requires tumor tissue examined by a pathologist. Imaging can show a mass or suspicious areas, but a scan cannot reliably determine the exact ovarian cancer subtype. Tissue obtained during a biopsy or surgery allows doctors to identify the tumor’s histology and grade.

Because LGSOC is uncommon and can resemble a serous borderline tumor or other ovarian neoplasms, an expert pathology review may be worthwhile. Ideally, the slides should be examined by a gynecologic pathologist familiar with rare ovarian tumors. A second review can confirm that “low-grade serous carcinoma” is truly the right label before major treatment decisions are made.

Tumor testing can uncover treatment-relevant changes

Many low-grade serous cancers are driven by abnormal signaling through the MAPK pathway, which includes proteins such as RAS, RAF, and MEK. Tumors may carry changes in genes such as KRAS, NRAS, or BRAF, although not every tumor has one of these mutations.

Comprehensive tumor profiling can be particularly important when the cancer recurs. In 2025, the FDA granted accelerated approval to avutometinib plus defactinib specifically for adults with recurrent, KRAS-mutated LGSOC who had previously received systemic therapy. That indication turns KRAS testing from an interesting laboratory detail into information that can directly influence treatment.

Patients with epithelial ovarian cancer are also generally advised to discuss inherited genetic testing. LGSOC is not as strongly linked to inherited BRCA mutations as high-grade serous cancer, but testing can still uncover hereditary risks relevant to the patient or family and may occasionally affect treatment choices.

4. Surgery Is Often the Cornerstone of Initial Treatment

For many patients, the first major treatment is surgery performed by a gynecologic oncologist. The goals are to confirm the diagnosis, determine the stage, and remove as much visible cancer as safely possible. This is called cytoreductive or debulking surgery.

Depending on the stage and location of disease, surgery may involve removal of one or both ovaries, the fallopian tubes, uterus, omentum, selected lymph nodes, and tumor deposits elsewhere in the abdomen. Occasionally, part of the bowel or another involved structure must be removed to achieve the best possible cytoreduction.

Because LGSOC is less responsive to standard chemotherapy than high-grade serous cancer, removing visible disease can be especially important. Preoperative chemotherapy may not shrink LGSOC as reliably as it shrinks more chemotherapy-sensitive ovarian tumors. For that reason, the decision between surgery first and medication first should be made by a multidisciplinary team with experience treating this subtype.

Fertility deserves an early conversation

Some patients are diagnosed during their reproductive years. In carefully selected people with disease confined to one ovary, fertility-sparing surgery may be considered. This usually means preserving the uterus and the unaffected ovary, but it is not appropriate in every situation.

Anyone concerned about future pregnancy should raise the subject before surgerynot while being wheeled toward the operating room, when the conversation becomes rather inconvenient. A gynecologic oncologist and fertility specialist can explain what is medically reasonable based on stage, tumor distribution, age, and personal goals.

5. Chemotherapy May Be Used, but Hormone Therapy Plays a Major Role

Paclitaxel plus carboplatin has historically been used after surgery for many patients with stage II to IV LGSOC. However, low-grade serous tumors are relatively resistant to platinum-based chemotherapy compared with high-grade serous tumors. That does not mean chemotherapy never works; it means expectations and alternatives should be discussed honestly.

Hormone therapy is particularly important because many LGSOC tumors express estrogen or progesterone receptors. Aromatase inhibitors such as letrozole, anastrozole, and exemestane lower estrogen levels and may slow hormone-sensitive tumor growth. These drugs are taken orally and are commonly considered as maintenance treatment or as therapy for recurrent disease.

A retrospective study of patients with stage II to IV low-grade serous ovarian or peritoneal cancer found substantially longer progression-free survival among those who received hormonal maintenance after surgery and chemotherapy compared with those who underwent observation. Because this was not a randomized trial, it cannot answer every question, but it helped establish endocrine maintenance as an important strategy.

Hormone therapy has its own side-effect checklist

Aromatase inhibitors are often easier to tolerate than cytotoxic chemotherapy, but “pill” does not mean “side-effect-free.” Possible problems include hot flashes, joint or muscle discomfort, vaginal dryness, and gradual bone loss. Patients taking long-term aromatase inhibitors may need bone-density monitoring, adequate calcium and vitamin D, weight-bearing exercise, or medication to protect bone health.

Researchers are also studying whether some patients with newly diagnosed advanced LGSOC can receive letrozole without chemotherapy. The NRG-GY019 phase III trial compares paclitaxel and carboplatin followed by letrozole with letrozole alone, reflecting an important effort to reduce unnecessary toxicity while maintaining cancer control.

6. Recurrent LGSOC Now Has More Targeted Treatment Options

Low-grade serous ovarian cancer has a significant tendency to recur. Fortunately, recurrence does not mean that every useful option has vanished behind a curtain. Depending on where the cancer returns, previous treatments, symptoms, mutation results, and the time since prior therapy, options may include another surgery, hormone therapy, chemotherapy, bevacizumab, a targeted drug, or a clinical trial. The National Cancer Institute lists surgery, cytotoxic chemotherapy, hormonal therapy, and targeted agents among potential approaches for recurrent disease.

Trametinib changed the treatment landscape

Trametinib is a MEK inhibitor that blocks part of the MAPK signaling pathway. In the GOG 281/LOGS randomized trial, trametinib produced longer median progression-free survival than the physician’s choice of standard therapyapproximately 13 months versus 7.2 months. It also improved the response rate and reduced the risk of progression or death by about 52%.

Trametinib can cause rash, diarrhea, fatigue, swelling, high blood pressure, and less common heart or eye complications. Patients generally need careful monitoring rather than a cheerful instruction to “take one and see what happens.”

A KRAS-directed combination received FDA accelerated approval

In May 2025, the FDA approved the combination of avutometinib, a RAF/MEK-targeting drug, and defactinib, a focal adhesion kinase inhibitor, for adults with KRAS-mutated recurrent LGSOC after prior systemic treatment. In the RAMP-201 study supporting the approval, 57 patients with measurable KRAS-mutated disease were evaluated, and the confirmed overall response rate was 44%.

The approval is accelerated, meaning continued approval may depend on confirmation of clinical benefit in additional studies. The combination may cause nausea, diarrhea, vomiting, fatigue, swelling, rash, changes in liver tests, muscle injury, and eye problems. Patients should promptly report vision changes, severe skin reactions, unusual muscle pain, or other concerning symptoms.

7. LGSOC Often Requires Long-Term Care, Not a One-and-Done Plan

The slower pace of LGSOC can lead to longer survival than is seen with some aggressive ovarian cancers, but it may also create a prolonged cycle of scans, treatments, medication changes, stable periods, and occasional recurrence. Patients may live with the diseaseor with the possibility of its returnfor many years.

Follow-up often includes symptom review, physical examinations, CA-125 testing when it was informative at diagnosis, and imaging when clinically appropriate. Experts caution that imaging may be more reliable than CA-125 alone for monitoring LGSOC. Bone-density evaluation is also important for patients taking long-term aromatase inhibitors.

Clinical trials deserve consideration at several points, not only after every standard treatment has failed. Rare cancers frequently advance through trial participation because large commercial studies are harder to conduct when the patient population is small. Current research is exploring new MAPK-pathway combinations, endocrine treatments, CDK inhibitors, and other molecular targets.

Useful questions to bring to an appointment

• Has my pathology been reviewed by a gynecologic pathologist?
• What is the exact stage and location of my disease?
• Was all visible tumor removed during surgery?
• Does my tumor express estrogen or progesterone receptors?
• Has the tumor been tested for KRAS, NRAS, BRAF, and other alterations?
• Would hormone maintenance therapy be appropriate?
• Should I consider trametinib or another targeted treatment?
• Are there clinical trials for which I may qualify?
• How will treatment affect fertility, menopause, bone health, and daily life?

Experiences Along the Low-Grade Serous Ovarian Cancer Journey

The following discussion reflects commonly reported patient experiences and practical lessons, not one person’s medical story.

One of the hardest parts of an LGSOC diagnosis can be the confusion created by the phrase “low-grade.” Family members may hear it and assume the cancer is minor. Patients may even wonder whether they are overreacting by feeling frightened. Then the medical team begins discussing major surgery, long-term medication, or advanced-stage disease, and the word “low” suddenly feels misleading.

Many patients find themselves explaining that low-grade serous ovarian cancer is slow-growing but still serious. A useful comparison is a plant with deep roots: it may not grow dramatically overnight, but it can be difficult to remove completely and may return. Having a simple explanation prepared can reduce the emotional burden of giving everyone an impromptu oncology lecture.

The period before diagnosis can be equally frustrating. A person may have visited several clinicians for bloating, constipation, urinary symptoms, or pelvic pressure. Tests may initially point toward digestive trouble, fibroids, ovarian cysts, or ordinary hormonal changes. Being told that symptoms are “probably nothing” can make patients question their instincts. Keeping a dated symptom diaryfrequency, severity, triggers, appetite changes, waist-size changes, and paincan make the pattern easier for a clinician to recognize.

After diagnosis, the amount of information can feel like being handed an advanced biology textbook during an earthquake. There are pathology terms, staging categories, receptor results, mutation reports, medication names, and trial numbers. Patients often benefit from bringing another person to appointments, recording the conversation when permitted, and requesting copies of pathology, operative, imaging, and molecular-testing reports. A dedicated folder may not cure cancer, but it can prevent important documents from disappearing into the same mysterious dimension that collects unmatched socks.

Surgery may bring both relief and grief. A successful operation can remove a substantial amount of disease, yet recovery may involve pain, fatigue, bowel changes, surgical menopause, changes in body image, or concerns about fertility. People who lose the ability to become pregnant may grieve even if they had not planned an immediate pregnancy. Those feelings are legitimate and may coexist with gratitude that the surgery was possible.

Long-term hormone therapy creates another distinctive experience. Taking a daily pill can look simple from the outside, but hot flashes, joint pain, sleep disruption, vaginal dryness, mood changes, and worries about bone health can accumulate. Patients sometimes remain silent because they assume these effects are the unavoidable price of treatment. In reality, symptom management may include exercise, physical therapy, sleep strategies, nonhormonal medications, sexual-health support, and bone-protective care. Reporting side effects is not complaining; it is treatment optimization.

Scan anxiety is also common. The days before imaging may bring insomnia, irritability, stomach upset, or an impressive inability to think about anything except the upcoming result. Some people schedule scans early in the day, avoid reading the patient portal alone, plan a calming activity afterward, or ask the clinic when results are likely to arrive. There is no gold medal for pretending the wait is easy.

Finally, many people discover that living with LGSOC requires two plans at once: a medical plan and a life plan. The medical plan covers treatments, scans, laboratory tests, and clinical trials. The life plan protects work, relationships, movement, nutrition, sexuality, emotional health, and ordinary joy. Cancer may occupy part of the calendar, but it does not deserve every square.

Conclusion

Low-grade serous ovarian cancer is rare, slow-growing, and biologically different from the more common high-grade serous subtype. Its relative resistance to chemotherapy makes expert surgery, hormone therapy, molecular testing, and targeted treatment especially important.

The most useful next step after diagnosis is often consultation with a gynecologic oncologist who regularly treats ovarian cancer and has access to expert pathology review. Patients should know the exact subtype, stage, hormone-receptor status, and molecular profile of their tumor. Those details can shape decisions about surgery, endocrine maintenance, trametinib, KRAS-directed therapy, and clinical trials.

Research progress has accelerated, including the emergence of effective MEK-pathway treatments and the first FDA-approved therapy specifically for KRAS-mutated recurrent LGSOC. The disease may be uncommon, but the treatment toolbox is no longer standing still.

SEO Information